Document Detail


Blastic plasmacytoid dendritic cell neoplasm: a single-center experience.
MedLine Citation:
PMID:  23135479     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from the precursor of the plasmacytoid dendritic cell. It is very rare and has only recently been recognized as a distinct entity. In this study, we report our experience of BPDCN to review the clinical, pathological features and treatment outcomes. A database at the Asan Medical Center was screened for all patients with BPDCN treated between 2000 and 2010. Seven patients were confirmed as BPDCN and included in this analysis. The median age of the patients was 40 years (range, 18-62 years), and four patients were male. Sites of disease involvement included the skin (n = 4), lymph node (n = 4), and peripheral blood/bone marrow (n = 2). Tumor cells were positive for CD4 (n = 5), CD56 (n = 6), and CD123 (n = 7). Six patients received multi-agent chemotherapy as first-line treatment, while one patient was given radiotherapy. The median progression-free survival was 8.6 months (range, 2.6-28.9 months) and overall survival was 15.1 months (range, 4.4-60.0 months) with a median follow-up period of 13.8 months (range, 1.9-29.9 months). Notably, all four patients with cutaneous involvement survived, whereas those without skin involvement succumbed to death, even though two of them were given salvage chemotherapy. In this study, patients with BPDCN showed various clinical, histological, and immunophenotypical features. Our experience warrants further examination of the prognostic significance of skin involvement in BPDCN.
Authors:
Ho Jung An; Dok Hyun Yoon; Shin Kim; Su-Jin Shin; Jooryung Huh; Kyoo-Hyung Lee; Cheolwon Suh
Related Documents :
19552699 - Cns and lung metastasis of sebaceous epithelioma in a dog.
1348799 - Subcurative chemotherapy and fatal post-treatment reactive encephalopathies in african ...
6295619 - The effect of cns metastases on the survival of patients with small cell cancer of the ...
15682069 - High-dose therapy and blood or marrow transplantation for non-hodgkin lymphoma with cen...
15704189 - Methotrexate levels and outcome in osteosarcoma.
12853349 - Occult central nervous system involvement in patients with metastatic breast cancer: pr...
16741919 - Psa velocity in conservatively managed bph: can it predict the need for bph-related inv...
24262269 - 49. 1-, 5- and 10-year high-grade disease-free survival after laser ablation of biopsy ...
7585679 - Radiotherapy in the treatment of low-grade astrocytomas. ii. the physical and cognitive...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-8
Journal Detail:
Title:  Annals of hematology     Volume:  -     ISSN:  1432-0584     ISO Abbreviation:  Ann. Hematol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9107334     Medline TA:  Ann Hematol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, South Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblasto...
Next Document:  Critical roles of RNA-binding proteins in miRNA biogenesis in Arabidopsis.